Answers are grounded in this paper and cite their sources.
Oral drug delivery to the colon remains a formidable challenge due to the harsh conditions of the upper gastrointestinal tract, including variable pH, enzymatic degradation, and limited mucosal permeability. β-Cyclodextrin (β-CD), a cyclic oligosaccharide with a hydrophobic cavity and hydrophilic exterior, offers a promising approach to overcome these barriers by forming stable inclusion complexes that protect sensitive drugs and modulate their release profile. This review explores the use of native and chemically modified β-CDs as functional carriers for colonic drug delivery, with a focus on hydrogel-based systems, mucoadhesive derivatives, and microbiota-responsive formulations. A critical review of over two decades of literature was conducted to evaluate the design, performance, and pharmacokinetic benefits of β-CD-loaded systems for intestine-specific therapeutic delivery. Evidence shows that β-CD hydrogels loaded with anti-inflammatory drugs, chemotherapeutics, and poorly soluble molecules achieve pH-sensitive, sustained drug release with improved mucosal adhesion and enhanced bioavailability. Thiolated β-CDs and hydroxypropyl derivatives improve the intestinal residence time and facilitate permeation across the mucus barrier. In additionf, S-protected thiolated β-CDs and NAC/arginine-modified β-CDs exhibit superior mucoadhesion and epithelial absorption, offering prolonged gastrointestinal retention. Formulations incorporating microbiota-triggered release mechanisms exhibit targeted activation in the colon due to fermentation/degradation of β-CDs by colonic Bacteroides, thereby reducing the systemic side effects. The manuscript also critically examines the application of β-cyclodextrin and its derivatives in advancing colon-targeted drug delivery through pH-responsive hydrogels synthesized via structural modifications, such as thiolation and hydroxypropylation that significantly enhance mucoadhesion, residence time, and drug permeation across intestinal barriers. The integration of β-CD with biopolymers and smart release triggers enables a controlled, site-specific therapeutic release with reduced systemic toxicity and improved pharmacokinetics. Overall, β-CD-based carriers enable multifunctional, site-specific delivery to the colon through a combination of physicochemical stabilization, mucoadhesion, and enzymatic responsiveness. Their application spans both small molecules and biologics, positioning β-CD as a foundational scaffold in the development of next-generation oral therapeutics for gastrointestinal disorders.
No takes yet. Share an insight, caveat, or question.
Sharma et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: